We are maintaining our Neutral stance on Endo Pharmaceuticals (NasdaqGS:ENDP - News) with a target price of $34.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and ...

Endo Pharmaceuticals’ plan to buy out pelvic care company American Medical Systems for $2.9 billion is another step in Endo’s quest to become more diversified, according to a report by Bloomberg ...

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune ...

Tennessee's Attorney General has filed a lawsuit against drug company Endo Pharmaceuticals for its contribution to the opioid epidemic. The suit alleges that Endo made unlawful and false claims about ...

Looking at all of its recent acquisitions, you might think Endo Pharmaceutical's (NMS:ENDP) business model echoes another firm's. One like Johnson & Johnson's (NYSE:JNJ - News). That makes sense. Endo ...

Endo Pharmaceuticals will undergo a rebranding initiative to expand from its core pain medicine business under the new name of Endo Health Solutions, according to a Philadelphia Business Journal ...

MALVERN, Pa., March 11, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals ...

DUBLIN and MALVERN, Pa., June 13, 2025 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (NDOI) ("Endo") today announced that their respective shareholders have provided the necessary ...

December 12, 2011 — Endo Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has approved a new crush-resistant formulation of Opana ER. The product will continue to go by ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The proposed sale comes nearly a ...